v3.26.3
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Disaggregation of Revenue [Line Items]        
Total revenue $ 151,754 $ 131,872 $ 441,146 $ 376,509
Biopharmaceutical and other revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 709 815 1,812 8,702
Biopharmaceutical revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 709 646 1,812 5,573
Contract manufacturing and testing        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0 $ 169 $ 0 $ 3,129